Page last updated: 2024-10-17

3,4-dihydroxyphenylacetic acid and Parkinson Disease

3,4-dihydroxyphenylacetic acid has been researched along with Parkinson Disease in 227 studies

3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.

Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)

Research Excerpts

ExcerptRelevanceReference
"The aim of the present study was to examine the influence of a unilateral 6-hydroxydopamine (6-OHDA)-induced partial lesion of both the substantia nigra pars compacta (SNc, A9) and retrorubral field (RRF, A8) on the tremor evoked by harmaline."7.786-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats. ( Berghauzen, K; Kolasiewicz, W; Kuter, K; Nowak, P; Ossowska, K; Schulze, G, 2012)
"3,4-Dihydroxyphenylacetaldehyde (DOPAL), the monoamine oxidase (MAO) metabolite of dopamine, plays a role in pathogenesis of Parkinson disease, inducing α-synuclein aggregation."3.91Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy. ( Burke, WJ; Gillespie, KN; Hsu, FF; Kumar, VB; Lakshmi, VM, 2019)
"Oxidative deamination of dopamine produces the highly toxic aldehyde 3,4-dihydroxyphenylacetaldehyde (DOPAL), enhanced production of which is found in post-mortem brains of Parkinson disease patients."3.81Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). ( Araujo, GD; Coelho-Cerqueira, E; Domont, GB; Eliezer, D; Follmer, C; Pinheiro, AS; Yatabe-Franco, DY, 2015)
"The aim of the present study was to examine the influence of a unilateral 6-hydroxydopamine (6-OHDA)-induced partial lesion of both the substantia nigra pars compacta (SNc, A9) and retrorubral field (RRF, A8) on the tremor evoked by harmaline."3.786-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats. ( Berghauzen, K; Kolasiewicz, W; Kuter, K; Nowak, P; Ossowska, K; Schulze, G, 2012)
"The long-term effect of the parkinsonism-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central monoaminergic neurons in young (2-3 months) and aging (12 months) C57BL/6 mice has been studied using neurochemical and immunocytochemical techniques."3.68Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis. ( Date, I; Felten, DL; Felten, SY, 1990)
"In four human controls, four cases of Parkinson's disease and three cases of amyotrophic lateral sclerosis analysis of dopamine, noradrenaline, serotonin and the metabolites 3,4-dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindoleacetic acid was performed in various segments of postmortem spinal cord."3.68Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis. ( Gavranovic, M; Gsell, W; Jellinger, K; Riederer, P; Schmidtke, A; Sofic, E, 1991)
"We investigated the effect of GM1 gangliosides on a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of Parkinson disease."3.68GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice. ( Albert, ML; Davoudi, H; Durso, R; Fazzini, E; Szabo, GK, 1990)
"Mean levels of the two hydrolases angiotensin-converting enzyme (ACE) and acetylcholinesterase (AChE), the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and total protein concentration were examined in cerebrospinal fluid (CSF) samples from a group of patients with dementia of the Alzheimer's type, a group of comparably demented patients with Parkinson's disease, and a neurologically healthy elderly control group."3.67Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study. ( Direnfeld, LK; Langlais, PJ; Marquis, JK; Nixon, RA; Volicer, L; Zubenko, GS, 1986)
" Hence, we propose to reevaluate this class of drugs as a disease-modifiers for PD, and we suggest that improved analysis of their pharmacology and bioavailability in the brain, together with a more precise patients stratification, should be considered before planning future clinical trials."2.72Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease. ( Antonini, A; Bubacco, L; Masato, A; Sandre, M, 2021)
"The most common is Parkinson's disease (PD), in which putamen dopamine content is drastically reduced."2.66The "Sick-but-not-Dead" Phenomenon Applied to Catecholamine Deficiency in Neurodegenerative Diseases. ( Goldstein, DS, 2020)
"Recent reports indicate that Parkinson's disease (PD) involves specific functional abnormalities in residual neurons - decreased vesicular sequestration of cytoplasmic catecholamines via the vesicular monoamine transporter (VMAT) and decreased aldehyde dehydrogenase (ALDH) activity."1.72The rat rotenone model reproduces the abnormal pattern of central catecholamine metabolism found in Parkinson's disease. ( Goldstein, DS; Halperin, R; Landau, R; Leibowitz, A; Sharabi, Y; Sullivan, P; Zibly, Z, 2022)
" DOPAL is well known to exhibit toxic effects on neuronal cells."1.62Oxidative Transformations of 3,4-Dihydroxyphenylacetaldehyde Generate Potential Reactive Intermediates as Causative Agents for Its Neurotoxicity. ( Ito, S; Ojika, M; Sugumaran, M; Tanaka, H; Wakamatsu, K, 2021)
"The synucleinopathies Parkinson's disease (PD), multiple system atrophy (MSA), and pure autonomic failure (PAF) are characterized by intra-cytoplasmic deposition of the protein alpha-synuclein and by catecholamine depletion."1.62Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies. ( Goldstein, DS; Holmes, C; Lamotte, G; Lenka, A; Sharabi, Y; Sullivan, P, 2021)
" Although this effect occurs with the formation of differently toxic products, the molecular basis of this inhibition is still unclear."1.62Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC. ( Acquasaliente, L; Bucciantini, M; Fongaro, B; Leri, M; Palazzi, L; Polverino de Laureto, P; Stefani, M, 2021)
"In rotenone-pre-treated cells, β-methylphenylalanine significantly increased cell viability and MMP, whereas ROS levels, apoptosis and fragmented mitochondria were reduced."1.56β-Methylphenylalanine exerts neuroprotective effects in a Parkinson's disease model by protecting against tyrosine hydroxylase depletion. ( Feng, Y; Ma, J; Yuan, L, 2020)
"In the catecholaldehyde hypothesis for Parkinson's disease, it is a critical driver of the selective loss of dopaminergic neurons that characterizes the disease."1.48Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein. ( Bax, A; DuMond, JF; Levine, RL; Monti, S; Werner-Allen, JW, 2018)
"We developed a diagnostic method for Parkinson's disease by simultaneously analyzing biogenic amines and their metabolites using reverse-phase high-performance liquid chromatography coupled with integrated pulsed amperometric detection (RP-HPLC-IPAD) method."1.48Development of a diagnostic method for Parkinson's disease by reverse-phase high-performance liquid chromatography coupled with integrated pulsed amperometric detection. ( Hong, SP; Huh, E; Jeong, JS; Oh, M; Oh, MS, 2018)
"In a model of early-stage Parkinson's disease induced by a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to Wistar rats, a neuroprotective effect of a new derivative of carnosine and α-lipoic acid (C/LA nanomicellar complex) was demonstrated."1.48Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease. ( Berezhnoy, DS; Fedorova, TN; Kulikova, OI; Lopachev, AV; Orlova, VS; Stvolinsky, SL, 2018)
"In a model of Parkinson's disease we demonstrate that repeated short-term expression of GDNF restores motor capabilities in 6-OHDA-lesioned rats."1.48Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector. ( Bähr, M; Cheng, S; Déglon, N; Konstantinova, P; Kügler, S; Liefhebber, J; Mazur, A; Pythoud, C; Raina, A; Rey, M; Streit, F; Tereshchenko, J; Vachey, G; Zimmer, V, 2018)
"Levodopa (l-DOPA, l-3,4-dihydroxyphenylalanine) is the most effective drug in the symptomatic treatment of Parkinson's disease (PD), but chronic use initiates a maladaptive process leading to l-DOPA-induced dyskinesia (LID)."1.46Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia. ( Andersen, AD; Binzer, M; Blaabjerg, M; Gramsbergen, JBP; Kamal, A; Kjaer, TW; Stenager, E; Thagesen, H, 2017)
"Zonisamide (ZNS) is an effective drug for not only motor symptoms but also non-motor symptoms in Parkinson's disease."1.46Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity. ( Asano, T; Hikawa, R; Takahashi, R; Uemura, MT; Yamakado, H, 2017)
" The enhanced stability and bioavailability of PEGylated rhFGF-2 make this molecule a great therapeutic candidate for neurodegenerative diseases such as PD and mood disorders."1.42PEGylated rhFGF-2 conveys long-term neuroprotection and improves neuronal function in a rat model of Parkinson's disease. ( Chen, G; Feng, J; Feng, W; Huang, Z; Niu, J; Shi, L; Wang, Y; Ye, C; Zhu, G, 2015)
"Current research on Parkinson's disease (PD) pathogenesis requires relevant animal models that mimic the gradual and progressive development of neuronal dysfunction and degeneration that characterizes the disease."1.42Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. ( Beauvais, G; Brundin, P; Escobar Galvis, ML; Feinstein, TN; Fuchs, J; Ghosh, A; Joshi, RL; Lipton, JW; Lundblad, M; Medicetty, S; Nordströma, U; Prochiantz, A; Pulikkaparambil Sasidharan, BC; Roholt, A; Steiner, JA, 2015)
"Parkinson disease with orthostatic hypotension (PD + OH) and the parkinsonian form of multiple system atrophy (MSA-P) can be difficult to distinguish clinically."1.42Plasma biomarkers of decreased vesicular storage distinguish Parkinson disease with orthostatic hypotension from the parkinsonian form of multiple system atrophy. ( Goldstein, DS; Holmes, C; Kopin, IJ; Sharabi, Y, 2015)
"Lactacystin is a selective UPS inhibitor recently used to destroy dopamine (DA) neurons in animal models of Parkinson's disease (PD)."1.42Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA. ( Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P, 2015)
"The mean Unified Parkinson's Disease Rating Scale scores (UPDRS) and the Parkinson's disease Questionnaire-39 (PDQ-39) were obtained before and after surgery."1.42Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease. ( Asahina, M; Higuchi, Y; Hirano, S; Kuwabara, S; Uchiyama, T; Yamamoto, T; Yamanaka, Y, 2015)
"Caffeine is a methylxanthine known as a non-selective inhibitor of A2A and A1 adenosine receptors in the brain and shown to be a neuroprotective drug."1.40Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions. ( Cavalheiro, EA; Cerqueira, GS; Correia, AO; de Barros Viana, GS; de Castro Brito, GA; Machado-Filho, JA; Montenegro, AB; Naffah-Mazzacoratti, Mda G; Neves, KR; Nobre, ME, 2014)
"Parkinson's disease is a multifactorial neurodegenerative disorder, characterized by a reduction of dopamine (DA) levels."1.40Novel orthogonal liquid chromatography methods to dose neurotransmitters involved in Parkinson's disease. ( Conte, C; Ianni, F; Lisanti, A; Natalini, B; Sardella, R; Scorzoni, S, 2014)
"A goldfish (Carassius auratus) model of Parkinson's disease (PD) was constructed by a single dose of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) according to previously reported methods."1.40(1)H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). ( Kong, L; Li, M; Liu, Q; Lu, Z; Wang, J; Wei, D; Yang, M, 2014)
"Following the intraperitoneal administration of silymarin (with MRP1, 2, 4 and 5 inhibitory effects), naringenin (with MRP1, 2 and 4 stimulatory effects), sulfinpyrazone (with MRP1, 4 and 5 inhibitory and MRP2 stimulatory effects) and allopurinol (with MRP4 stimulatory effect in doses of 100 mg/kg, 100 mg/kg, 100 mg/kg and 60 mg/kg, respectively, for one week before and after the administration of MPTP in C57B/6 mice in acute dosing regimen the striatal concentrations of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid has been measured using high-performance liquid chromatography."1.39Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice. ( Klivényi, P; Plangár, I; Szalárdy, L; Vécsei, L; Zádori, D, 2013)
" VU0364770 showed efficacy alone or when administered in combination with L-DOPA or an adenosine 2A (A2A) receptor antagonist currently in clinical development (preladenant)."1.38The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. ( Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N, 2012)
"ADHs are of interest in Parkinson's disease (PD) since these compounds can be harmful to dopamine (DA) neurons."1.38Adh1 and Adh1/4 knockout mice as possible rodent models for presymptomatic Parkinson's disease. ( Anvret, A; Belin, AC; Duester, G; Felder, MR; Galter, D; Gellhaar, S; Lindqvist, E; Lundströmer, K; Pernold, K; Ran, C; Westerlund, M, 2012)
"Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder of mature and older individuals."1.36Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. ( Charlton, CG; King, J; Mackey, V; Muthian, G, 2010)
"The symptoms of restless legs syndrome (RLS) have a circadian pattern and central nervous system dopamine has been implicated in the pathogenesis of the condition."1.35Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. ( Engelland, S; Kripke, DF; Parsons, L; Poceta, JS, 2009)
"Pure autonomic failure (PAF) and Parkinson's disease (PD) share several clinical laboratory abnormalities; however, PAF is not associated with parkinsonism."1.35Central dopamine deficiency in pure autonomic failure. ( Bernson, M; Carmona, G; Goldstein, DS; Holmes, C; Imrich, R; Mizrahi, N; Sato, T; Sharabi, Y; Vortmeyer, AO, 2008)
"Our data show that disease progression produces an early large decay of DA levels, followed by a stabilization."1.35Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. ( Brusa, L; Fedele, E; Fornai, F; Galati, S; Hainsworth, AH; Lunardi, G; Moschella, V; Pierantozzi, M; Pisani, A; Rossi, S; Stanzione, P; Stefani, A; Tropepi, D, 2009)
"Parkinson's disease is a neurodegenerative disorder associated with progressive loss of dopaminergic cells in the substantia nigra."1.33Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease. ( Cho, Y; Choi, HJ; Hwang, O; Lee, SY, 2005)
"The MFB lesion model mimics end-stage Parkinson's disease."1.33Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. ( Ebinger, G; Michotte, Y; Sarre, S; Yuan, H, 2005)
" Because of their ability to combat oxidative stress, diet derived phenolic compounds continue to be considered as potential agents for long-term use in PD."1.33Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. ( Aruoma, OI; Datla, KP; Dexter, DT; Parkar, S; Rai, DK; Zbarsky, V, 2005)
"The aetiology of idiopathic Parkinson's disease (PD) is poorly defined but environmental aggression may be relevant."1.33Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice. ( Cavada, C; Close, RM; Cuadrado, A; de Sagarra, MR; Fernández-Ruiz, J; Jackson-Lewis, V; Montero, C; Rojo, AI; Salazar, M; Sánchez-González, MA, 2006)
"Dopaminergic lesion produced catalepsy and hypoactivity."1.32Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. ( Schmidt, WJ; Srinivasan, J, 2004)
"3,4-Dihydroxyphenylacetaldehyde (DOPAL) is a toxic metabolite formed by the oxidative deamination of dopamine."1.313,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. ( Eisenhofer, G; Harvey-White, J; Kirk, K; Kopin, IJ; Lamensdorf, I; Nechustan, A, 2000)
"Ten patients with advanced Parkinson's disease (Hoehn & Yahr stage IV) were medicated with tolcapone."1.31COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. ( Buhmann, C; Oechsner, M; Strauss, J; Stuerenburg, HJ, 2002)
"L-3,4-Dihydroxyphenylalanine (L-DOPA) is a common and effective treatment for Parkinson's disease, but dyskinesia continues to be a serious adverse effect with chronic use."1.31Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease. ( Akiyama, A; Nakazato, T, 2002)
"Investigations of gene therapy for Parkinson's disease have focused primarily on strategies that replace tyrosine hydroxylase."1.30Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. ( Bencsics, C; Kang, UJ; Wachtel, SR, 1997)
"That thalidomide has activity in this model suggests that an inflammatory process may be involved in the induction of lesions by MPTP in DAergic neurons."1.30Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. ( Boireau, A; Bordier, F; Dubédat, P; Impérato, A; Pény, C, 1997)
" Plasma L-dopa was evaluated in relation to dosage and postdose sampling time in 71 outpatients with Parkinson disease."1.29Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor. ( Copeland, LG; Dutton, J; Playfer, JR; Roberts, NB, 1993)
" Plasma levodopa and levodopa metabolite pharmacokinetic profiles were determined using standard techniques."1.29A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease. ( O'Connell, MT; Patsalos, PN; Quinn, NP; Wenning, GK, 1995)
"The oxidant stress theory of Parkinson's disease (PD) hypothesizes that levodopa treatment may be potentially harmful and this is supported by studies demonstrating levodopa toxicity to cultured dopaminergic neurons."1.29Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease. ( Ahlskog, JE; Low, PA; Nickander, KK; O'Brien, JF; Tyce, GM; Uitti, RJ, 1996)
"Furthermore, 6 of 15 untreated Parkinson's disease patients (40%) displayed markedly elevated plasma concentrations of the catecholamine MAO metabolites, DOPAC or DOPEG."1.29Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases. ( Ahlskog, JE; Kokmen, E; O'Brien, JF; Petersen, RC; Tyce, GM; Uitti, RJ, 1996)
"Six patients with Parkinson's disease (PD) and therapeutic response fluctuations (RF) on levodopa treatment participated in an open-label trial of L-deprenyl (Eldepryl) in conjunction with Sinemet."1.28L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease. ( Cedarbaum, JM; Clark, M; Harts, A; Kutt, H; Silvestri, M, 1990)
"In experimental Parkinson's disease, we studied the effects of chronic administration (30 days), withdrawal, and reinstitution of bromocriptine."1.27Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats. ( Baden, DR; Kenny, AM; Murrin, LC; Pfeiffer, RF; Schneider, MB, 1986)
" These results indicate that chronic administration of either bromocriptine or L-Dopa will reverse the DA receptor denervation supersensitivity in striatum seen following 6-OHDA lesion."1.27Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease. ( Deupree, JD; Murrin, LC; Pfeiffer, RF; Schneider, MB, 1984)
"Patients with Parkinson's disease have a decrement in homovanillic acid that is reversed by treatment with L-3,4-dihydroxyphenylalanine."1.27Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. ( Aguado, EG; de Yebenes, JG; Mena, MA, 1984)
"5 g of levodopa daily for up to six months and in 30 patients receiving levodopa (800-1,000 mg) combined with a dopa decarboxylase inhibitor, benserazide (200-250 mg)."1.25Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations. ( Rinne, UK; Siirtola, T; Sonninen, V, 1975)
"We believe that neuropharmacologic bladder neck obstruction may be caused by the alpha-adrenergic properties of the metabolites of levodopa."1.25Effects of levodopa on the bladder outlet. ( Krane, RJ; Murdock, MI; Olsson, CA; Sax, DS, 1975)

Research

Studies (227)

TimeframeStudies, this research(%)All Research%
pre-199032 (14.10)18.7374
1990's46 (20.26)18.2507
2000's64 (28.19)29.6817
2010's67 (29.52)24.3611
2020's18 (7.93)2.80

Authors

AuthorsStudies
Ito, S1
Tanaka, H1
Ojika, M1
Wakamatsu, K1
Sugumaran, M1
Landau, R1
Halperin, R1
Sullivan, P10
Zibly, Z1
Leibowitz, A1
Goldstein, DS21
Sharabi, Y14
Liguori, C1
Stefani, A2
Fernandes, M1
Cerroni, R1
Mercuri, NB1
Pierantozzi, M2
Fongaro, B2
Cappelletto, E1
Sosic, A1
Spolaore, B1
Polverino de Laureto, P2
Nadig, APR1
Huwaimel, B1
Alobaida, A1
Khafagy, ES1
Alotaibi, HF1
Moin, A1
Lila, ASA1
M, S1
Krishna, KL1
Zhou, J1
Li, J1
Papaneri, AB1
Cui, G1
Jinsmaa, Y5
Isonaka, R1
Kostrzewa, JP1
Kostrzewa, RM1
Laranjinha, J4
Nunes, C4
Ledo, A1
Lourenço, C1
Rocha, B1
Barbosa, RM2
Bagnoli, E1
Diviney, T1
FitzGerald, U1
Kao, CY1
Xu, M1
Wang, L1
Lin, SC1
Lee, HJ1
Duraine, L1
Bellen, HJ1
Tsai, SY1
Tsai, MJ1
Feng, Y1
Ma, J1
Yuan, L1
Masato, A1
Sandre, M1
Antonini, A1
Bubacco, L1
Holmes, C12
Lamotte, G1
Lenka, A1
Kremer, T1
Taylor, KI1
Siebourg-Polster, J1
Gerken, T1
Staempfli, A1
Czech, C1
Dukart, J1
Galasko, D1
Foroud, T1
Chahine, LM1
Coffey, CS1
Simuni, T1
Weintraub, D1
Seibyl, J1
Poston, KL1
Toga, AW1
Tanner, CM1
Marek, K1
Hutten, SJ1
Dziadek, S1
Trenkwalder, C1
Pagano, G1
Mollenhauer, B1
Palazzi, L1
Leri, M1
Acquasaliente, L1
Stefani, M1
Bucciantini, M1
Uemura, MT1
Asano, T1
Hikawa, R1
Yamakado, H1
Takahashi, R1
Sasidharakurup, H1
Melethadathil, N1
Nair, B1
Diwakar, S1
Vanle, BC1
Florang, VR2
Murry, DJ1
Aguirre, AL1
Doorn, JA3
Hoon, M1
Petzer, JP1
Viljoen, F1
Petzer, A1
Werner-Allen, JW1
Monti, S1
DuMond, JF1
Levine, RL1
Bax, A1
Lopez, GJ1
Wu, T1
Oh, M1
Huh, E1
Oh, MS1
Jeong, JS1
Hong, SP1
Kulikova, OI1
Berezhnoy, DS1
Stvolinsky, SL1
Lopachev, AV1
Orlova, VS1
Fedorova, TN1
Cheng, S1
Tereshchenko, J1
Zimmer, V1
Vachey, G1
Pythoud, C1
Rey, M1
Liefhebber, J1
Raina, A1
Streit, F1
Mazur, A1
Bähr, M3
Konstantinova, P1
Déglon, N1
Kügler, S1
Joniec-Maciejak, I1
Wawer, A1
Turzyńska, D1
Sobolewska, A1
Maciejak, P1
Szyndler, J1
Mirowska-Guzel, D1
Płaźnik, A1
Lima, VA1
do Nascimento, LA1
Eliezer, D2
Follmer, C2
Stiles, L1
Zheng, Y1
Smith, PF1
Kumar, VB2
Hsu, FF2
Lakshmi, VM1
Gillespie, KN1
Burke, WJ6
Pagan, FL1
Hebron, ML1
Wilmarth, B1
Torres-Yaghi, Y1
Lawler, A1
Mundel, EE1
Yusuf, N1
Starr, NJ1
Arellano, J1
Howard, HH1
Peyton, M1
Matar, S1
Liu, X2
Fowler, AJ1
Schwartz, SL1
Ahn, J1
Moussa, C1
Lv, DJ1
Li, LX1
Chen, J1
Wei, SZ1
Wang, F1
Hu, H1
Xie, AM1
Liu, CF1
Petri, D1
Pum, M1
Vesper, J1
Huston, JP1
Schnitzler, A1
Miller, GW2
Alter, S1
Strong, R4
Mash, DC3
Kopin, IJ10
Han, B2
Hu, J1
Shen, J1
Gao, Y1
Lu, Y2
Wang, T2
Yamamoto, T2
Uchiyama, T2
Sakakibara, R1
Taniguchi, J1
Kuwabara, S2
Machado-Filho, JA1
Correia, AO1
Montenegro, AB1
Nobre, ME1
Cerqueira, GS1
Neves, KR1
Naffah-Mazzacoratti, Mda G1
Cavalheiro, EA1
de Castro Brito, GA1
de Barros Viana, GS1
Plangár, I1
Zádori, D1
Szalárdy, L1
Vécsei, L2
Klivényi, P1
Feng, G1
Zhang, Z2
Bao, Q1
Zhou, L1
Jiang, J1
Li, S1
Zhu, G1
Chen, G2
Shi, L1
Feng, J2
Wang, Y2
Ye, C1
Feng, W1
Niu, J1
Huang, Z1
Sardella, R1
Scorzoni, S1
Conte, C1
Lisanti, A1
Ianni, F1
Natalini, B1
Casida, JE2
Ford, B1
Cooney, A1
Jin, HJ1
Song, MY1
Zhao, H1
Lu, Z1
Wang, J2
Li, M1
Liu, Q1
Wei, D2
Yang, M1
Kong, L1
Nordströma, U1
Beauvais, G1
Ghosh, A1
Pulikkaparambil Sasidharan, BC1
Lundblad, M1
Fuchs, J1
Joshi, RL1
Lipton, JW1
Roholt, A1
Medicetty, S1
Feinstein, TN1
Steiner, JA1
Escobar Galvis, ML1
Prochiantz, A1
Brundin, P1
Saal, KA1
Koch, JC1
Tatenhorst, L1
Szegő, EM1
Ribas, VT1
Michel, U1
Tönges, L1
Lingor, P1
Konieczny, J1
Czarnecka, A1
Kamińska, K1
Lenda, T1
Nowak, P2
Sharma, N1
Nehru, B1
Coelho-Cerqueira, E1
Yatabe-Franco, DY1
Araujo, GD1
Pinheiro, AS1
Domont, GB1
Higuchi, Y1
Asahina, M1
Hirano, S1
Yamanaka, Y1
Rai, SN1
Yadav, SK1
Singh, D1
Singh, SP1
Targa, AD1
Rodrigues, LS1
Noseda, AC1
Aurich, MF1
Andersen, ML1
Tufik, S1
da Cunha, C1
Lima, MM1
Andersen, AD1
Blaabjerg, M1
Binzer, M1
Kamal, A1
Thagesen, H1
Kjaer, TW1
Stenager, E1
Gramsbergen, JBP1
Xu, L1
Liu, LX1
Chen, WF1
Lunardi, G1
Galati, S1
Tropepi, D1
Moschella, V1
Brusa, L1
Rossi, S1
Fornai, F1
Fedele, E1
Stanzione, P1
Hainsworth, AH1
Pisani, A1
Chung, CY1
Koprich, JB1
Hallett, PJ1
Isacson, O1
Whittaker, N1
Heredia-Moya, J1
Li, XM1
Ma, HB1
Ma, ZQ1
Li, LF1
Xu, CL1
Qu, R1
Ma, SP1
Marcellino, D1
Suárez-Boomgaard, D1
Sánchez-Reina, MD1
Aguirre, JA1
Yoshitake, T1
Yoshitake, S1
Hagman, B1
Kehr, J1
Agnati, LF1
Fuxe, K1
Rivera, A1
di Matteo, V1
Pierucci, M1
Di Giovanni, G1
Dragani, LK1
Murzilli, S1
Poggi, A1
Esposito, E1
Muthian, G1
Mackey, V1
King, J1
Charlton, CG1
Shi, D1
Lv, L1
Li, L2
Gu, P1
Gao, J1
Miao, Y1
Hu, W1
Basile, MJ1
Belin, AC2
Westerlund, M2
Anvret, A2
Lindqvist, E2
Pernold, K2
Ogren, SO1
Duester, G2
Galter, D2
Panneton, WM1
Gan, Q1
Galvin, JE2
Gautam, AH1
Zeevalk, GD3
Anderson, DG1
Mariappan, SV1
Buettner, GR1
Almeida, L2
Shchepinov, MS1
Chou, VP1
Pollock, E1
Langston, JW2
Cantor, CR1
Molinari, RJ1
Manning-Boğ, AB2
Rybakowska, I1
Szreder, G1
Kaletha, K1
Barwina, M1
Waldman, W1
Sein Anand, J1
Ran, C1
Gellhaar, S1
Lundströmer, K1
Felder, MR1
Jones, CK1
Bubser, M1
Thompson, AD1
Dickerson, JW1
Turle-Lorenzo, N1
Amalric, M2
Blobaum, AL1
Bridges, TM1
Morrison, RD1
Jadhav, S1
Engers, DW1
Italiano, K1
Bode, J1
Daniels, JS1
Lindsley, CW1
Hopkins, CR1
Conn, PJ1
Niswender, CM1
Meng, T1
Zheng, ZH1
Liu, TT1
Lin, L1
Kotraiah, V1
Pallares, D1
Toema, D1
Kong, D1
Beausoleil, E1
Wey, MC1
Fernandez, E1
Martinez, PA1
Frank, T1
Klinker, F1
Falkenburger, BH1
Laage, R1
Lühder, F1
Göricke, B1
Schneider, A1
Neurath, H1
Desel, H1
Liebetanz, D1
Weishaupt, JH1
Wu, G1
Lu, ZH1
Kulkarni, N1
Ledeen, RW1
Vermeer, LM1
Kolasiewicz, W1
Kuter, K1
Berghauzen, K1
Schulze, G1
Ossowska, K1
Fitzmaurice, AG1
Rhodes, SL1
Lulla, A1
Murphy, NP1
Lam, HA1
O'Donnell, KC1
Barnhill, L1
Cockburn, M1
Sagasti, A1
Stahl, MC1
Maidment, NT1
Ritz, B1
Bronstein, JM1
McCormack, AL1
Thiruchelvam, M1
Thiffault, C1
Cory-Slechta, DA1
Di Monte, DA1
Selikhova, MV1
Kogan, BM1
Serkin, GV1
Gusev, EI1
Kato, H1
Araki, T1
Imai, Y1
Takahashi, A1
Itoyama, Y1
Kaur, D1
Yantiri, F1
Rajagopalan, S1
Kumar, J1
Mo, JQ1
Boonplueang, R1
Viswanath, V1
Jacobs, R1
Yang, L1
Beal, MF1
DiMonte, D1
Volitaskis, I1
Ellerby, L1
Cherny, RA1
Bush, AI1
Andersen, JK1
Li, SW3
Williams, EA1
Nonneman, R1
Zahm, DS1
Gajjar, TM1
Anderson, LI1
Dluzen, DE3
Romero-Ramos, M1
Venero, JL1
Garcia-Rodriguez, S1
Ayala, A1
Machado, A1
Cano, J1
Legare, ME1
Hanneman, WH1
Srinivasan, J1
Schmidt, WJ1
Youdim, MB1
Stephenson, G1
Ben Shachar, D1
Datla, KP2
Bennett, RD1
Zbarsky, V2
Ke, B1
Liang, YF1
Higa, T1
Bahorun, T1
Aruoma, OI2
Dexter, DT3
Gluck, MR2
Santana, LA1
Granson, H1
Yahr, MD2
Nakao, N1
Shintani-Mizushima, A1
Kakishita, K1
Itakura, T1
Wang, X2
Zhang, H1
Wang, K1
He, Q1
Agrawal, AK1
Shukla, S1
Chaturvedi, RK1
Seth, K1
Srivastava, N2
Ahmad, A1
Seth, PK1
Yuan, H2
Sarre, S3
Ebinger, G3
Michotte, Y3
Choi, HJ1
Lee, SY1
Cho, Y1
Hwang, O1
Rajda, C1
Dibó, G1
Bergquist, J1
Asanuma, M2
Miyazaki, I1
Diaz-Corrales, FJ1
Shimizu, M1
Tanaka, K2
Ogawa, N2
Sasaki, M1
Sanada, H1
Parkar, S1
Rai, DK1
Jiang, H2
Jiang, Q1
Liu, W1
Fitzsimmons, DF1
Moloney, TC1
Dowd, E1
Liu, B1
Mazzulli, JR1
Mishizen, AJ1
Giasson, BI1
Lynch, DR1
Thomas, SA1
Nakashima, A1
Nagatsu, T1
Ota, A1
Ischiropoulos, H1
Rojo, AI1
Montero, C1
Salazar, M1
Close, RM1
Fernández-Ruiz, J1
Sánchez-González, MA1
de Sagarra, MR1
Jackson-Lewis, V3
Cavada, C1
Cuadrado, A1
Hamaue, N1
Ogata, A1
Terado, M1
Ohno, K1
Kikuchi, S1
Sasaki, H1
Tashiro, K1
Hirafuji, M1
Minami, M1
Landau, AM1
Kouassi, E1
Siegrist-Johnstone, R1
Desbarats, J1
Jana, S1
Maiti, AK1
Bagh, MB1
Banerjee, K1
Das, A1
Roy, A1
Chakrabarti, S1
Grandoso, L1
Ponce, S1
Manuel, I1
Arrúe, A1
Ruiz-Ortega, JA1
Ulibarri, I1
Orive, G1
Hernández, RM1
Rodríguez, A1
Rodríguez-Puertas, R1
Zumárraga, M1
Linazasoro, G1
Pedraz, JL1
Ugedo, L1
Poceta, JS1
Parsons, L1
Engelland, S1
Kripke, DF1
Recchia, A1
Rota, D1
Debetto, P1
Peroni, D1
Guidolin, D1
Negro, A1
Skaper, SD1
Giusti, P1
Bentho, O1
Sato, T2
Moak, J1
Imrich, R2
Conant, S1
Eldadah, BA1
Bernson, M1
Mizrahi, N1
Carmona, G1
Vortmeyer, AO1
Rajeswari, A1
Sabesan, M1
Melamed, E4
Hefti, F2
Liebman, J1
Schlosberg, AJ1
Wurtman, RJ2
Zigmond, MJ3
Stricker, EM1
Mena, MA1
Aguado, EG1
de Yebenes, JG1
Schneider, MB2
Murrin, LC2
Pfeiffer, RF2
Deupree, JD1
Cooper, DR1
Marrel, C1
Testa, B1
van de Waterbeemd, H1
Quinn, N1
Jenner, P2
Marsden, CD1
Karoum, F1
Chuang, LW1
Eisler, T1
Calne, DB1
Liebowitz, MR1
Quitkin, FM1
Klein, DF1
Wyatt, RJ1
Reches, A1
Fahn, S1
Scatton, B1
Rouquier, L1
Javoy-Agid, F2
Agid, Y1
Bierer, DW1
Quebbemann, AJ1
Hagan, RM1
Raxworthy, MJ1
Gulliver, PA1
Eldrup, E1
Mogensen, P1
Jacobsen, J1
Pakkenberg, H1
Christensen, NJ1
Tohgi, H1
Abe, T1
Yamazaki, K1
Saheki, M1
Takahashi, S1
Tsukamoto, Y1
Loeffler, DA2
LeWitt, PA3
DeMaggio, AJ2
Juneau, PL2
Milbury, PE1
Matson, WR1
Moukhles, H1
Nieoullon, A2
Daszuta, A1
Finberg, JP1
Bankiewicz, KS1
Espino, A1
Llorens, J1
Calopa, M1
Bartrons, R1
Rodriguez-Farré, E1
Ambrosio, S1
Wesemann, W2
Blaschke, S1
Solbach, M1
Grote, C1
Clement, HW1
Riederer, P3
Muthane, U1
Ramsay, KA1
Donaldson, D1
Fernando, S1
Ferreira, M1
Przedborski, S2
Hossain, MA1
Weiner, N1
Sian, J1
Rose, S1
Hindmarsh, JG1
Mann, VM1
Cooper, JM1
Wells, FR1
Daniel, SE2
Lees, AJ2
Schapira, AH1
Mattammal, MB2
Chung, HD2
Benetello, P1
Furlanut, M1
Zara, G1
Baraldo, M1
Hassan, E1
Dutton, J1
Copeland, LG1
Playfer, JR1
Roberts, NB1
Wenning, GK1
O'Connell, MT1
Patsalos, PN1
Quinn, NP1
Haring, JH1
Raghu, G1
Ahlskog, JE2
Uitti, RJ2
Low, PA1
Tyce, GM2
O'Brien, JF2
Nickander, KK1
Yokoyama, R1
Shibata, T1
Dawson, VL1
Dawson, TM1
Hastings, TG2
Lewis, DA2
Petersen, RC1
Kokmen, E1
Maruyama, W1
Naoi, M1
Narabayashi, H1
Howells, DW1
Liberatore, GT1
Wong, JY1
Donnan, GA1
Tatton, WG1
Wadia, JS1
Ju, WY1
Chalmers-Redman, RM1
Tatton, NA1
Bowenkamp, KE1
Lapchak, PA2
Hoffer, BJ1
Miller, PJ1
Bickford, PC1
Havaich, MK1
Wachtel, SR1
Bencsics, C1
Kang, UJ1
Boireau, A1
Bordier, F1
Dubédat, P1
Pény, C1
Impérato, A1
Dluzen, D1
Araujo, DM1
Hilt, DC1
Sheng, J1
Jiao, S1
Yoshida, K1
Higuchi, H1
Kamata, M1
Yoshimoto, M1
Shimizu, T1
Hishikawa, Y1
Brannan, T1
Prikhojan, A1
Martínez-Tica, J1
Izurieta-Sánchez, P1
Spencer, JP1
Marsden, DC1
Halliwell, B1
Zhang, J1
Kravtsov, V1
Amarnath, V1
Picklo, MJ1
Graham, DG1
Montine, TJ1
Moy, LY1
Sonsalla, PK2
Lamensdorf, I1
Eisenhofer, G1
Harvey-White, J1
Nechustan, A1
Kirk, K1
Serra, PA1
Esposito, G1
Enrico, P1
Mura, MA1
Migheli, R1
Delogu, MR1
Miele, M1
Desole, MS1
Grella, G1
Miele, E1
Rabinovic, AD1
Xu, K1
Meissner, W1
Paul, G1
Reum, T1
Reese, R1
Sohr, R1
Morgenstern, R1
Kupsch, A1
Kristal, BS1
Conway, AD1
Brown, AM1
Jain, JC1
Ulluci, PA1
Rathke-Hartlieb, S1
Kahle, PJ1
Neumann, M1
Ozmen, L1
Haid, S1
Okochi, M1
Haass, C1
Schulz, JB1
Tillerson, JL1
Cohen, AD1
Philhower, J1
Schallert, T1
Abe, K1
Taguchi, K1
Wasai, T1
Ren, J1
Utsunomiya, I1
Shinohara, T1
Miyatake, T1
Sano, T1
Iacovitti, L1
Stull, ND1
Jin, H1
Lin, TS1
Minteer, S1
Barthwal, MK1
Dikshit, M1
Oechsner, M1
Buhmann, C1
Strauss, J1
Stuerenburg, HJ1
Nakazato, T1
Akiyama, A1
Hashimoto, T1
Yabe-Nishimura, C1
Kirik, D1
Rosenblad, C1
Burger, C1
Lundberg, C1
Johansen, TE1
Muzyczka, N1
Mandel, RJ1
Björklund, A1
Riaz, SS1
Jauniaux, E1
Stern, GM1
Bradford, HF1
Peyrin, L1
Cottet-Emard, JM1
Claustre, B1
Narasimhachari, N1
Leiner, K1
Brown, C1
Hoehn, MM3
Crowley, TJ2
Rutledge, CO3
Bronaugh, RL1
MacMurtry, RJ1
Murdock, MI1
Olsson, CA1
Sax, DS1
Krane, RJ1
Watson, E1
Wilk, S1
Siirtola, T1
Sonninen, V1
Rinne, UK1
Lach, B1
Grimes, D1
Benoit, B1
Minkiewicz-Janda, A1
Russ, H1
Mihatsch, W1
Gerlach, M1
Przuntek, H1
Sofic, E1
Gsell, W1
Gavranovic, M1
Schmidtke, A1
Jellinger, K1
Jolicoeur, FB1
Rivest, R1
Drumheller, A1
Prell, GD1
Khandelwal, JK1
Burns, RS1
Blandina, P1
Morrishow, AM1
Green, JP1
Date, I1
Felten, DL1
Felten, SY1
Horellou, P1
Marlier, L1
Privat, A1
Darchen, F1
Scherman, D1
Henry, JP1
Mallet, J1
Carlsson, A1
Fornstedt, B1
Cedarbaum, JM1
Silvestri, M1
Clark, M1
Harts, A1
Kutt, H1
Harnois, C1
Di Paolo, T1
Fazzini, E1
Durso, R1
Davoudi, H1
Szabo, GK1
Albert, ML1
Conte-Devolx, B1
Grino, M1
Castanas, E1
Guillaume, V1
Tonon, MC1
Vaudry, H1
Oliver, C1
Parenti, M1
Flauto, C1
Parati, E1
Vescovi, A1
Groppetti, A1
Shigetomi, S1
Stahl, SM1
Faull, KF1
Barchas, JD1
Berger, PA1
Collins, MA1
Neafsey, EJ1
Zubenko, GS1
Marquis, JK1
Volicer, L1
Direnfeld, LK1
Langlais, PJ1
Nixon, RA1
Kenny, AM1
Baden, DR1
Nakamura, S2
Fukuda, H1
Hara, K2
Fukuyama, H1
Kameyama, M2
Youngster, SK1
Heikkila, RE1
Sershen, H1
Hashim, A1
Lajtha, A1
Iijima, S1
Globus, M1
Rosenthal, J1
Uzzan, A1
Yu, PH1
Bailey, BA1
Durden, DA1
Boulton, AA1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?[NCT03104725]Phase 16 participants (Actual)Interventional2017-09-25Terminated (stopped due to Difficulty with recruitment and participant accrual due to study eligibility criteria and required study procedures (e.g., multiple lumbar punctures).)
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease[NCT02424708]Phase 245 participants (Actual)Interventional2015-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Mean Percent Change in Cys-DA/DOPAC Between Pre and Post-treatment Lumbar Puncture With and Without N-acetylcysteine (NAC)

Patients with Parkinson's Disease (PD) who took N-acetylcysteine (NAC), and healthy volunteers who did not take NAC, each had two separate lumbar punctures (LPs) to obtain spinal fluid. The spinal fluid samples were used to measure the ratio of the brain chemical called 5-S-cysteinyl-dopamine (Cys-DA) to the brain chemical called 3,4-Dihydroxyphenylacetic acid (Cys-DOPAC). Dopamine has 2 metabolic fates. One is the breakdown of dopamine by an enzyme to form DOPAC. The other is spontaneous oxidation to form Cys-DA. The ratio of Cys-DA/DOPAC may reflect these relative fates. If NAC reduced spontaneous oxidation to Cys-DA, then the ratio Cys-DA/DOPAC would decrease between LP 1 and LP 2, which would be reflected as a percent decrease. (NCT03104725)
Timeframe: All participants underwent a baseline LP. For PD participants, the second LP occurred approximately 2 hours after the participant had taken NAC the last NAC dose. For HV participants the second LP takes place approximately 48 hours after the first LP.

Interventionpercent change (Mean)
Healthy Volunteers (HVs)50.1
Parkinson's Disease (PD) Patients27.2

The Mean Percent Change in Cerebrospinal Fluid (CSF) Concentration of 5-S-cysteinyl-dopamine (Cys-DA) Pre and Post-N-acetylcysteine (NAC) Treatment

Patients with Parkinson's Disease (PD) who took N-acetylcysteine (NAC), and healthy volunteers who did not take NAC, each had two separate lumbar punctures (LP 1 and LP 2) to obtain spinal fluid. The spinal fluid samples were used to measure the amount of a brain chemical called 5-S-cysteinyl-dopamine (Cys-DA). The primary outcome measure is the mean change in CSF Cys-DA levels between pre and post-NAC treatment, which is calculated as the difference of CSF Cys-DA levels at pre-treatment (LP 1) and post-treatment (LP 2) divided by CSF Cys-DA at pre-treatment (LP 1). A greater percent decrease in Cys-DA levels in the brain would suggest that NAC may contribute to a reduction in the oxidation of brain dopamine, while a smaller percent decrease would suggest that NAC had no effect on the oxidation of brain dopamine. (NCT03104725)
Timeframe: All participants underwent a baseline LP. For PD participants, the second LP occurred approximately 2 hours after the participant had taken NAC the last NAC dose. For HV participants the second LP takes place approximately 48 hours after the first LP.

Interventionpercent change (Mean)
Healthy Volunteers (HVs)45.7
Parkinson's Disease (PD) Patients20.1

Mean Ratio of Cys-DA/DOPAC Pre and Post-treatment Lumbar Puncture With and Without N-acetylcysteine (NAC)

Patients with Parkinson's Disease (PD) who took N-acetylcysteine (NAC), and healthy volunteers who did not take NAC, each had two separate lumbar punctures (LPs) to obtain spinal fluid. The spinal fluid samples were used to measure the ratio of the brain chemical called 5-S-cysteinyl-dopamine (Cys-DA) to the brain chemical called 3,4-Dihydroxyphenylacetic acid (Cys-DOPAC). Dopamine has 2 possible metabolic fates or processes of degradation. One fate is the breakdown of Dopamine by an enzyme to form DOPAC. The other fate is spontaneous oxidation to form Cys-DA. The ratio of Cys-DA to DOPAC may reflect these relative fates. If NAC reduced spontaneous oxidation to Cys-DA, then the ratio Cys-DA/DOPAC ratio would decrease between LP 1 and LP 2. (NCT03104725)
Timeframe: All participants underwent a baseline LP. For PD participants, the second LP occurred approximately 2 hours after the participant had taken NAC the last NAC dose. For HV participants the second LP takes place approximately 48 hours after the first LP.

,
Interventionratio (Mean)
Cys-DA/DOPAC LP1Cys-DA/DOPAC LP2
Healthy Volunteers (HVs)0.120.05
Parkinson's Disease (PD) Patients0.160.13

Reviews

11 reviews available for 3,4-dihydroxyphenylacetic acid and Parkinson Disease

ArticleYear
The Peculiar Facets of Nitric Oxide as a Cellular Messenger: From Disease-Associated Signaling to the Regulation of Brain Bioenergetics and Neurovascular Coupling.
    Neurochemical research, 2021, Volume: 46, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Animals; Brain; Energy Metabolism; Humans; Mitoch

2021
The "Sick-but-not-Dead" Phenomenon Applied to Catecholamine Deficiency in Neurodegenerative Diseases.
    Seminars in neurology, 2020, Volume: 40, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Autonomic Nervous System Diseases; Dopamine; Humans; Lewy Body Disea

2020
Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease.
    Current neuropharmacology, 2021, Volume: 19, Issue:10

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Dopamine; Humans; Oxidative Stress; Parkinson Disease

2021
Nitric oxide and dopamine metabolism converge via mitochondrial dysfunction in the mechanisms of neurodegeneration in Parkinson's disease.
    Archives of biochemistry and biophysics, 2021, 06-15, Volume: 704

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopaminergic Neurons; Humans; Mitochondria; Nitri

2021
The heart of PD: Lewy body diseases as neurocardiologic disorders.
    Brain research, 2019, 01-01, Volume: 1702

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Catecholamines; Dopamine; Heart; Humans; Lewy Bodie

2019
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.
    Pharmacology & therapeutics, 2014, Volume: 144, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Apoptosis; Catecholamines; Humans; Lipid P

2014
[Reactive oxygen species and 3,4-dihydroxyphenylacetaldehyde in pathogenesis of Parkinson disease].
    Przeglad lekarski, 2011, Volume: 68, Issue:8

    Topics: 3,4-Dihydroxyphenylacetic Acid; Brain; Humans; Oxidative Stress; Parkinson Disease; Reactive Oxygen

2011
3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease.
    Current drug targets. CNS and neurological disorders, 2003, Volume: 2, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Drug Delivery Systems; Humans; Neuroprotective Agents; Park

2003
[3,4-Dihydroxyphenylacetic acid (DOPAC)].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 8

    Topics: 3,4-Dihydroxyphenylacetic Acid; Addison Disease; Adrenal Gland Neoplasms; Alzheimer Disease; Biomark

2005
Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
    Acta neuropathologica, 2006, Volume: 112, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Dopamine; Humans; Oxidative Stress; Parkinson Disea

2006
(-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.
    Journal of neural transmission. Supplementum, 1996, Volume: 48

    Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Animals; Apoptosis; Cells, Cultured; Gene Express

1996

Trials

4 trials available for 3,4-dihydroxyphenylacetic acid and Parkinson Disease

ArticleYear
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.
    Pharmacology research & perspectives, 2019, Volume: 7, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aged, 80 and over; alpha-Synuclein; Biomarkers; Brain;

2019
The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Experimental neurology, 2004, Volume: 188, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain Tissue Transpla

2004
The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
    Journal of the neurological sciences, 1996, Volume: 139, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antiparkinson Agents; Biogenic Monoamines; Cerebral Ventricle

1996
Conjugation of L-DOPA and its metabolites after oral and intravenous administration to Parkinsonian patients.
    Biochemical pharmacology, 1975, Jul-15, Volume: 24, Issue:13-14

    Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Aged; Clinical Trials as Topic; Dopamine; Dose

1975

Other Studies

212 other studies available for 3,4-dihydroxyphenylacetic acid and Parkinson Disease

ArticleYear
Oxidative Transformations of 3,4-Dihydroxyphenylacetaldehyde Generate Potential Reactive Intermediates as Causative Agents for Its Neurotoxicity.
    International journal of molecular sciences, 2021, Oct-29, Volume: 22, Issue:21

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Neurotoxicity Syndromes; Oxidation-Reduction; Par

2021
The rat rotenone model reproduces the abnormal pattern of central catecholamine metabolism found in Parkinson's disease.
    Disease models & mechanisms, 2022, 01-01, Volume: 15, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catecholamines; Dopamine; Parkinson Disease; Rats; Rotenone

2022
Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinson's Disease: A Cerebrospinal Fluid-Based Study.
    Journal of Parkinson's disease, 2022, Volume: 12, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Amyloid beta-Peptides; Biomarkers; Dopamine; Glucose; Humans; Lactat

2022
3,4-Dihydroxyphenylethanol and 3,4-dihydroxyphenylacetic acid affect the aggregation process of E46K variant of α-synuclein at different extent: Insights into the interplay between protein dynamics and catechol effect.
    Protein science : a publication of the Protein Society, 2022, Volume: 31, Issue:7

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Catechols; Dopamine; Humans; Parkinson Disease; Phe

2022
Manganese chloride (MnCl
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 155

    Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids; Animals; Apoptosis; Brain-Derived Neurotrophic Factor;

2022
AJ76 and UH232 as potential agents for diagnosing early-stage Parkinson's disease.
    Neuropharmacology, 2023, 03-15, Volume: 226

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopamine Antagonists; Haloperidol; Homovanillic A

2023
3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing
    The Journal of pharmacology and experimental therapeutics, 2020, Volume: 372, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; alpha-Synuclein; Antioxidants; Cell Line; Copper; Do

2020
p-Chloroamphetamine-Enhanced Neostriatal Dopamine Exocytosis in Rats Neonatally Co-lesioned with 6-OHDA and 5,7-DHT: Relevance to Parkinson's Disease.
    Neurotoxicity research, 2020, Volume: 37, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; 5,7-Dihydroxytryptamine; Animals; Animals, Newborn; Dopamine; Exocyt

2020
Dysregulation of astrocytic mitochondrial function following exposure to a dopamine metabolite: Implications for Parkinson's disease.
    The European journal of neuroscience, 2021, Volume: 53, Issue:9

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Dopamine; Mitochondria; Parkinson Disease; Rats

2021
Elevated COUP-TFII expression in dopaminergic neurons accelerates the progression of Parkinson's disease through mitochondrial dysfunction.
    PLoS genetics, 2020, Volume: 16, Issue:6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Brain; Cell Line; Cell Line, Tumor;

2020
β-Methylphenylalanine exerts neuroprotective effects in a Parkinson's disease model by protecting against tyrosine hydroxylase depletion.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:17

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aminobutyrates; Animals; Cell Survival; Dopamine; Humans; Membrane P

2020
Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies.
    Journal of neurochemistry, 2021, Volume: 158, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Cohort Studies; Dopamine; Dopaminergic Neurons; Female; Homova

2021
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
    Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:8

    Topics: 3,4-Dihydroxyphenylacetic Acid; Homovanillic Acid; Humans; Levodopa; Neurotransmitter Agents; Parkin

2021
Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC.
    International journal of molecular sciences, 2021, Jun-02, Volume: 22, Issue:11

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amyloid; Cell Proliferation; Dopamine; Dopaminergic

2021
Zonisamide inhibits monoamine oxidase and enhances motor performance and social activity.
    Neuroscience research, 2017, Volume: 124

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Astrocytes; Brain; Dopamine; Explorat

2017
A Systems Model of Parkinson's Disease Using Biochemical Systems Theory.
    Omics : a journal of integrative biology, 2017, Volume: 21, Issue:8

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Biomarkers; Brain; Cell Death; Computer Simulation;

2017
Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde.
    Biochemical and biophysical research communications, 2017, 10-14, Volume: 492, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Enzyme Induction; Glyceraldehyde-3-Phosphate Dehy

2017
The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
    Molecules (Basel, Switzerland), 2017, Nov-27, Volume: 22, Issue:12

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biological Availability; Carbidopa; Corpus Striatum; Dopami

2017
Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein.
    Biochemistry, 2018, 03-06, Volume: 57, Issue:9

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Cross-Linking Reagents; Humans; Isoindoles; Models,

2018
Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease.
    Parkinsonism & related disorders, 2018, Volume: 50

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Biomarkers; Disease Progression; Dopamine; Female; Foll

2018
Development of a diagnostic method for Parkinson's disease by reverse-phase high-performance liquid chromatography coupled with integrated pulsed amperometric detection.
    Journal of pharmaceutical and biomedical analysis, 2018, May-10, Volume: 153

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Biomarkers; Chromatography, High Pressure

2018
Neuroprotective effect of the carnosine - α-lipoic acid nanomicellar complex in a model of early-stage Parkinson's disease.
    Regulatory toxicology and pharmacology : RTP, 2018, Volume: 95

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Brain; Carnosine; Dopamine; Homovanillic Acid

2018
Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
    Experimental neurology, 2018, Volume: 309

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Disease Models, Animal; Gene Expression

2018
Octanoic acid prevents reduction of striatal dopamine in the MPTP mouse model of Parkinson's disease.
    Pharmacological reports : PR, 2018, Volume: 70, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caprylates; C

2018
Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
    ACS chemical neuroscience, 2019, 01-16, Volume: 10, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylation; alpha-Synuclein; Dopamine; Dopaminergic Neurons; Humans

2019
The effects of electrical stimulation of the peripheral vestibular system on neurochemical release in the rat striatum.
    PloS one, 2018, Volume: 13, Issue:10

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Electric Stimulation; Electric S

2018
Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
    European journal of pharmacology, 2019, Feb-15, Volume: 845

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; alpha-Synuclein; Animals; Indans; Neuroprotective Agents;

2019
Sleep deprivation caused a memory defects and emotional changes in a rotenone-based zebrafish model of Parkinson's disease.
    Behavioural brain research, 2019, 10-17, Volume: 372

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cognition; Disease Models, Animal; Dopamine; Emotions; Male

2019
GABAA-receptor activation in the subthalamic nucleus compensates behavioral asymmetries in the hemiparkinsonian rat.
    Behavioural brain research, 2013, Sep-01, Volume: 252

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Animals; Disease Models, Animal; Diz

2013
Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease.
    Journal of neurochemistry, 2013, Volume: 126, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldeh

2013
Neuroprotective effect of hydroxysafflor yellow A on 6-hydroxydopamine-induced Parkinson's disease in rats.
    European journal of pharmacology, 2013, Aug-15, Volume: 714, Issue:1-3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Chalcone; Gene Expression Re

2013
The subthalamic activity and striatal monoamine are modulated by subthalamic stimulation.
    Neuroscience, 2014, Feb-14, Volume: 259

    Topics: 3,4-Dihydroxyphenylacetic Acid; Action Potentials; Animals; Biogenic Monoamines; Chromatography, Hig

2014
Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
    Behavioural brain research, 2014, May-01, Volume: 264

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Apomorphine; Brain; Caffeine; Cytokines;

2014
Assessment of the role of multidrug resistance-associated proteins in MPTP neurotoxicity in mice.
    Ideggyogyaszati szemle, 2013, Nov-30, Volume: 66, Issue:11-12

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Allopurinol; Animals;

2013
Protective effect of chinonin in MPTP-induced C57BL/6 mouse model of Parkinson's disease.
    Biological & pharmaceutical bulletin, 2014, Volume: 37, Issue:8

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat

2014
PEGylated rhFGF-2 conveys long-term neuroprotection and improves neuronal function in a rat model of Parkinson's disease.
    Molecular neurobiology, 2015, Volume: 51, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Apoptosis; Astrocytes; Behavior, Animal; Biolo

2015
Novel orthogonal liquid chromatography methods to dose neurotransmitters involved in Parkinson's disease.
    Journal of pharmaceutical and biomedical analysis, 2014, Volume: 98

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebral Cortex; Chromatography, High Pressure Liquid; Chro

2014
Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease.
    Chemical research in toxicology, 2014, Aug-18, Volume: 27, Issue:8

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Aldehydes; Animals; Antifungal Agents; Benom

2014
A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
    Parkinsonism & related disorders, 2014, Volume: 20, Issue:11

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Mo

2014
(1)H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Chemico-biological interactions, 2014, Nov-05, Volume: 223

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani

2014
Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
    Neurobiology of disease, 2015, Volume: 73

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autophagy; Corpus Striatum; Disease Models, Animal; Disease

2015
AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
    Neurobiology of disease, 2015, Volume: 73

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Dependovirus; Disease Models, Animal; Do

2015
Plasma biomarkers of decreased vesicular storage distinguish Parkinson disease with orthostatic hypotension from the parkinsonian form of multiple system atrophy.
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2015, Volume: 25, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Biomarkers; Case-Control Studies; Comorbidity; Cross-Sectional

2015
Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
    Behavioural brain research, 2015, Apr-15, Volume: 283

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Cell Count; Corpus Striatum; Dopamine; Dose

2015
Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.
    Parkinsonism & related disorders, 2015, Volume: 21, Issue:6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Aldehyde Dehydrogenase; Corpus Striatum; Di

2015
Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
    Molecular neurobiology, 2016, Volume: 53, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetophenones; Animals; Cytokines; Disease Models, Animal; Dopaminer

2016
Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
    The Journal of biological chemistry, 2015, Nov-13, Volume: 290, Issue:46

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amyloid; Animals; Cell Membrane; Dopamine; Dopamine

2015
Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Area Under Curve; Catecholamines; Deep B

2015
Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.
    The Journal of pharmacology and experimental therapeutics, 2016, Volume: 356, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopaminergic Neurons; Dose-Response Relationship,

2016
Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
    Journal of chemical neuroanatomy, 2016, Volume: 71

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani

2016
Unraveling a new circuitry for sleep regulation in Parkinson's disease.
    Neuropharmacology, 2016, Volume: 108

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine Agonists; Dopamine D2 Receptor An

2016
3,4-Dihydroxyphenylethanol (Hydroxytyrosol) Mitigates the Increase in Spontaneous Oxidation of Dopamine During Monoamine Oxidase Inhibition in PC12 Cells.
    Neurochemical research, 2016, Volume: 41, Issue:9

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dopamine Agents; Monoamine Oxidase; Monoamine Oxi

2016
Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.
    Parkinsonism & related disorders, 2016, Volume: 31

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Animals; Catechols; Dihydroxyphenylalanine; Dopamine; Female;

2016
Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Journal of neurochemistry, 2017, Volume: 141, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aging; Antiparkinson Agents; Catecholamines; Dopamine;

2017
[Effect and mechanism on dopamine contents of striatum in rat model of Parkinson's disease ginsenoside Rg1].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2008, Volume: 33, Issue:15

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Central Nervous System Agents; Corpus Str

2008
Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease.
    Parkinsonism & related disorders, 2009, Volume: 15, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Age of Onset; Aged; Disease Progression; Dopamine; Dyskinesias; Homo

2009
Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.
    Proceedings of the National Academy of Sciences of the United States of America, 2009, Dec-29, Volume: 106, Issue:52

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Line; Corpus Striatum; Dopamine; Female; Gene Expressi

2009
Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde.
    Clinical chemistry, 2010, Volume: 56, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Chromatography, Liqui

2010
Ameliorative and neuroprotective effect in MPTP model of Parkinson's disease by Zhen-Wu-Tang (ZWT), a traditional Chinese medicine.
    Journal of ethnopharmacology, 2010, Jul-06, Volume: 130, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Cor

2010
On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079.
    Journal of neural transmission (Vienna, Austria : 1996), 2010, Volume: 117, Issue:6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Analysis of Variance; Animals; Brain; Cell Count;

2010
Intake of tomato-enriched diet protects from 6-hydroxydopamine-induced degeneration of rat nigral dopaminergic neurons.
    Journal of neural transmission. Supplementum, 2009, Issue:73

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carotenoids; Disease Models, Animal; Dopamine; Functional L

2009
Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.
    Neuroscience, 2010, Sep-01, Volume: 169, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Birth

2010
The effect of lentivirus-mediated TH and GDNF genetic engineering mesenchymal stem cells on Parkinson's disease rat model.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2011, Volume: 32, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antigens, CD; Corpus Striatum; Diseas

2011
Catechols in post-mortem brain of patients with Parkinson disease.
    European journal of neurology, 2011, Volume: 18, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Brain Chemistry; Dopamine; Female; Humans;

2011
Modeling Parkinson's disease genetics: altered function of the dopamine system in Adh4 knockout mice.
    Behavioural brain research, 2011, Mar-01, Volume: 217, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Dehydrogenase; Amphetamine; Analysis of Variance; Animals; A

2011
The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis.
    PloS one, 2010, Dec-13, Volume: 5, Issue:12

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Dopamine; Glial Fibrillary Acidic Protein

2010
Characterization of reduced and oxidized dopamine and 3,4-dihydrophenylacetic acid, on brain mitochondrial electron transport chain activities.
    Biochimica et biophysica acta, 2011, Volume: 1807, Issue:7

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopamine; Electron Transport; Electron Transport Cha

2011
Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone.
    The Journal of biological chemistry, 2011, Jul-29, Volume: 286, Issue:30

    Topics: 3,4-Dihydroxyphenylacetic Acid; Benzoquinones; Cyclooxygenase 2; Free Radicals; Humans; Oxidation-Re

2011
Nitric oxide and DOPAC-induced cell death: from GSH depletion to mitochondrial energy crisis.
    Molecular and cellular neurosciences, 2011, Volume: 48, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; bcl-2-Associated X Protein; Cell Death; Dop

2011
Natural toxin implicated as triggering Parkinson's disease.
    Pakistan journal of biological sciences : PJBS, 2011, Feb-01, Volume: 14, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Humans; Neurons; Neurotoxins; Parkinson Disease

2011
Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
    Toxicology letters, 2011, Nov-30, Volume: 207, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Linolenic Acid;

2011
Adh1 and Adh1/4 knockout mice as possible rodent models for presymptomatic Parkinson's disease.
    Behavioural brain research, 2012, Feb-01, Volume: 227, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Dehydrogenase; Analysis of Variance; Animals; Apomorphine; C

2012
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 2012, Volume: 340, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling

2012
Contralateral retinal dopamine decrease and melatonin increase in progression of hemiparkinsonium rat.
    Neurochemical research, 2012, Volume: 37, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Disease Progression;

2012
Identification of aldehyde dehydrogenase 1A1 modulators using virtual screening.
    Journal of enzyme inhibition and medicinal chemistry, 2013, Volume: 28, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Aldehyde De

2013
Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease.
    PloS one, 2012, Volume: 7, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Body Weight; Cognition Disorders; C

2012
Pegylated granulocyte colony-stimulating factor conveys long-term neuroprotection and improves functional outcome in a model of Parkinson's disease.
    Brain : a journal of neurology, 2012, Volume: 135, Issue:Pt 6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Chroma

2012
Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans.
    Journal of neuroscience research, 2012, Volume: 90, Issue:10

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Aging; Animals; Antiparkinson Agents; Blott

2012
Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.
    Brain research, 2012, Sep-20, Volume: 1474

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Catechols; Cell Line; Chromatography, High Pressure Liqui

2012
6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats.
    Brain research, 2012, Oct-05, Volume: 1477

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Central Nervous System Stimulants; Cereb

2012
Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Jan-08, Volume: 110, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Benomyl; Dopaminergic Neurons; Flow

2013
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
    Neurobiology of disease, 2002, Volume: 10, Issue:2

    Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environm

2002
[Catecholamine metabolism in different forms of Parkinson's disease].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2002, Volume: 102, Issue:9

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Catecholamines; Data Interpretation, Statistical; Dihydroxyphe

2002
Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.
    Journal of the neurological sciences, 2003, Apr-15, Volume: 208, Issue:1-2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Caprylates; Corpus Striatum; Disease Models, An

2003
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.
    Neuron, 2003, Mar-27, Volume: 37, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Wes

2003
3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
    Brain research, 2003, Nov-07, Volume: 989, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Disease Models, Animal; Dopamine; Dose-Response Relationshi

2003
Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system.
    Journal of neural transmission (Vienna, Austria : 1996), 2003, Volume: 110, Issue:11

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Drug Interactions; Estrogens; Female; Methampheta

2003
Semichronic inhibition of glutathione reductase promotes oxidative damage to proteins and induces both transcription and translation of tyrosine hydroxylase in the nigrostriatal system.
    Free radical research, 2003, Volume: 37, Issue:9

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Blotting, Western; Carmustine; Corpus Striatum; Dopamine; D

2003
Genetic, biochemical, and characterization of neurological mutant 3, a new mouse model for Parkinson's disease.
    Genetics and molecular research : GMR, 2003, Sep-30, Volume: 2, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Chromosome Mapping; Disease Models, Animal

2003
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Behavioural brain research, 2004, May-05, Volume: 151, Issue:1-2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal

2004
Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
    Annals of the New York Academy of Sciences, 2004, Volume: 1012

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain; Brocresine;

2004
The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    The Journal of pharmacy and pharmacology, 2004, Volume: 56, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Beverages; Corpus Striatum; Dopamine; Dose-Re

2004
Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity.
    Journal of neural transmission (Vienna, Austria : 1996), 2004, Volume: 111, Issue:6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal;

2004
Distinct efficacy of pre-differentiated versus intact fetal mesencephalon-derived human neural progenitor cells in alleviating rat model of Parkinson's disease.
    International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience, 2004, Volume: 22, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cell Differentiation; Cell Division; Cell

2004
Olfactory ensheathing cell transplantation restores functional deficits in rat model of Parkinson's disease: a cotransplantation approach with fetal ventral mesencephalic cells.
    Neurobiology of disease, 2004, Volume: 16, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Transp

2004
Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
    Brain research, 2004, Nov-05, Volume: 1026, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Chromatography, High Pressur

2004
Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson's disease and catecholamine-associated diseases.
    Journal of neurochemistry, 2004, Volume: 91, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Catecholamines; Cell Respiration; Dopamine

2004
Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease.
    Neurochemistry international, 2005, Volume: 46, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Benzoquinones; Biopterins; Cell Death; Cell

2005
Increased dopamine content in lymphocytes from high-dose L-Dopa-treated Parkinson's disease patients.
    Neuroimmunomodulation, 2005, Volume: 12, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Antiparkinson Agents; Dopamine; Dose-Response Relations

2005
Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
    Journal of neuroscience methods, 2005, May-15, Volume: 144, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Behavior, Animal; Brain Chemistry; Ce

2005
Synergistic inhibition of respiration in brain mitochondria by nitric oxide and dihydroxyphenylacetic acid (DOPAC). Implications for Parkinson's disease.
    Neurochemistry international, 2005, Volume: 47, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Cell Respiration; Dopamine; Dose-Response Relationsh

2005
Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
    Neurological research, 2005, Volume: 27, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Benzoquinones;

2005
Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease.
    Free radical research, 2005, Volume: 39, Issue:10

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Curcumin; Disease Models, Animal; Dopamine; F

2005
Parkin suppresses the expression of monoamine oxidases.
    The Journal of biological chemistry, 2006, Mar-31, Volume: 281, Issue:13

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; B-Lymphocytes; Binding Sites; Cell Line, Transformed; Cell

2006
Further validation of the corridor task for assessing deficit and recovery in the hemi-Parkinsonian rat: restoration of bilateral food retrieval by dopamine receptor agonism.
    Behavioural brain research, 2006, May-15, Volume: 169, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Chromatogra

2006
Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice.
    Neuroendocrinology, 2006, Volume: 83, Issue:5-6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Androgens; Animals; Dopamine; Dopamine Agents; Dose-Response Relatio

2006
Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2006, Sep-27, Volume: 26, Issue:39

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino Acid Substitution; Animals; Catechols; Cell D

2006
Persistent penetration of MPTP through the nasal route induces Parkinson's disease in mice.
    The European journal of neuroscience, 2006, Volume: 24, Issue:7

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Acetylcholinesterase;

2006
Brain catecholamine alterations and pathological features with aging in Parkinson disease model rat induced by Japanese encephalitis virus.
    Neurochemical research, 2006, Volume: 31, Issue:12

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Brain; Brain Chemistry; Catecholamines; Dopamine; En

2006
Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle.
    Movement disorders : official journal of the Movement Disorder Society, 2007, Feb-15, Volume: 22, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Central Nervous System Depressants; Chromatography, High Pr

2007
Dopamine but not 3,4-dihydroxy phenylacetic acid (DOPAC) inhibits brain respiratory chain activity by autoxidation and mitochondria catalyzed oxidation to quinone products: implications in Parkinson's disease.
    Brain research, 2007, Mar-30, Volume: 1139

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzoquinones; Brain; Dopamine; Electron Transport; Electro

2007
Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats.
    International journal of pharmaceutics, 2007, Oct-01, Volume: 343, Issue:1-2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cell Line; Cell Survival; Corpus Striatum

2007
Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease.
    Sleep medicine, 2009, Volume: 10, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Biogenic Monoamines; Chromatography, High Pressure Liquid; Cir

2009
Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Neurobiology of disease, 2008, Volume: 30, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; alpha-Synuclein; Analysis of Variance; Animals; A

2008
Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy.
    Parkinsonism & related disorders, 2008, Volume: 14, Issue:8

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Biomarkers; Brain; Dihydroxyphenylalanine; Dop

2008
Central dopamine deficiency in pure autonomic failure.
    Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2008, Volume: 18, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Autonomic Nervous System Diseases; Brain; Catechols; Dihydroxy

2008
Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
    Inflammopharmacology, 2008, Volume: 16, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Curcumin; Dis

2008
Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease.
    Nature, 1980, Feb-21, Volume: 283, Issue:5749

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Stem; Disease Models, Animal; Dopa Decarboxylase; Dop

1980
Parkinson's disease: studies with an animal model.
    Life sciences, 1984, Jul-02, Volume: 35, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Disease Models, Animal; Dopamine; Electrophysiology;

1984
Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method.
    Acta neurologica Scandinavica, 1984, Volume: 69, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Chromatography, High Pressure Liquid; Depression;

1984
Tyrosine administration increases striatal dopamine release in rats with partial nigrostriatal lesions.
    Proceedings of the National Academy of Sciences of the United States of America, 1980, Volume: 77, Issue:7

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Homovani

1980
Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Clinical neuropharmacology, 1984, Volume: 7, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromocriptine; Corpus Striatum; Disease Models, Animal; Dop

1984
L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease.
    Clinical neuropharmacology, 1984, Volume: 7, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Anim

1984
Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment.
    Neurology, 1982, Volume: 32, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Amphetamines; Biogenic Amines; Carbidopa; Depression; Drug Co

1982
3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
    Annals of neurology, 1982, Volume: 12, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug

1982
Dopamine deficiency in the cerebral cortex in Parkinson disease.
    Neurology, 1982, Volume: 32, Issue:9

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Cerebral Cortex; Dopamine; Hippocampus; Homovanillic Acid; Hum

1982
Interference of levodopa and its metabolites with colorimetry of uric acid.
    Clinical chemistry, 1981, Volume: 27, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Colorimetry; Dopamine; Homovanillic Acid; Humans; Levodopa; Parkinso

1981
Benserazide and carbidopa as substrates of catechol-O-methyltransferase: new mechanism of action in Parkinson's disease.
    Biochemical pharmacology, 1980, Dec-01, Volume: 29, Issue:23

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Benzyl Compounds; Carbidopa; Catechol O-Methyl

1980
CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease.
    Acta neurologica Scandinavica, 1995, Volume: 92, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dihydroxyphenylalanine; Dopamine; Epinephrine; Female;

1995
Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement.
    Neuroscience letters, 1995, Jun-16, Volume: 192, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Met

1995
Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid.
    Journal of neural transmission. Parkinson's disease and dementia section, 1995, Volume: 9, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Corpus Striatum; Dopamine; Homovanillic Acid; L

1995
Complex deficits on reaction time performance following bilateral intrastriatal 6-OHDA infusion in the rat.
    The European journal of neuroscience, 1995, May-01, Volume: 7, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Frontal

1995
Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats.
    Journal of neurochemistry, 1995, Volume: 65, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dialysis; Dopamine; Homovanill

1995
Cerebrospinal dopamine metabolites in rats after intrastriatal administration of 6-hydroxydopamine or 1-methyl-4-phenylpyridinium ion.
    Brain research, 1995, Jan-09, Volume: 669, Issue:1

    Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; gam

1995
Intranigral injected iron progressively reduces striatal dopamine metabolism.
    Journal of neural transmission. Parkinson's disease and dementia section, 1994, Volume: 8, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Ferric Compounds; Injections; Ma

1994
Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice.
    Experimental neurology, 1994, Volume: 126, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Biomarkers; Calbindin 1; Calbindins;

1994
Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 1993, Volume: 267, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biopterins; Brain Diseases; Carbidopa; Corpus Striatum; Cyc

1993
Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease.
    Annals of neurology, 1994, Volume: 35, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Brain Chemistry; Caudate Nucleus; Dopamine; Electron Transport

1994
Confirmation of a dopamine metabolite in parkinsonian brain tissue by gas chromatography-mass spectrometry.
    Journal of chromatography, 1993, May-05, Volume: 614, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Brain; Dopamine; Gas Chromatography-Mass Sp

1993
Assessment of the dopaminergic lesion in Parkinson's disease by CSF markers.
    Advances in neurology, 1993, Volume: 60

    Topics: 3,4-Dihydroxyphenylacetic Acid; Brain; Dopamine; Homovanillic Acid; Humans; Levodopa; Neurons; Parki

1993
Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
    European neurology, 1993, Volume: 33, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Blood-Brain Barrier; Carbidopa; Delayed-

1993
Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor.
    Clinical chemistry, 1993, Volume: 39, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Aromatic Amino Acid Decarboxylase Inhibitor

1993
A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 1995, Volume: 10, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Antitubercular Agents; Dopa Decarboxylase; Homovanillic Acid; Humans

1995
An endogenous dopaminergic neurotoxin: implication for Parkinson's disease.
    Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration, 1995, Volume: 4, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Culture Techniques; Dopamine; Dopamine Uptake Inhibitors; g

1995
Levodopa and deprenyl treatment effects on peripheral indices of oxidant stress in Parkinson's disease.
    Neurology, 1996, Volume: 46, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Aged, 80 and over; Cysteinyldopa; Humans; Levodopa; Mal

1996
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
    Proceedings of the National Academy of Sciences of the United States of America, 1996, May-14, Volume: 93, Issue:10

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebellum; Corpus Striatum; Dopamine; Dopamine Agents; Enz

1996
Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?
    Journal of neural transmission. Supplementum, 1995, Volume: 45

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine Agonists; D

1995
Reactive dopamine metabolites and neurotoxicity: implications for Parkinson's disease.
    Advances in experimental medicine and biology, 1996, Volume: 387

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catechols; Cysteine; Dopamine; Free Radicals; Histocytochem

1996
Plasma catechols and monoamine oxidase metabolites in untreated Parkinson's and Alzheimer's diseases.
    Journal of the neurological sciences, 1996, Volume: 136, Issue:1-2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Alzheimer Disease; Blood Platelets; Catecho

1996
Dopaminergic responses to striatal damage.
    Journal of the neurological sciences, 1996, Volume: 139, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Brain Tissue Transplantation; Corpus Striatum; Dihyd

1996
Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats.
    Experimental neurology, 1997, Volume: 145, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chromatography, High Pressure Liquid; Dis

1997
Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation.
    Clinical neuropharmacology, 1994, Volume: 17, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Dopamine; Glutathione; Glutathione Di

1994
Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
    Journal of neurochemistry, 1997, Volume: 69, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aromatic-L-Amino-Acid Decarboxylases; Catecholamines; Cell

1997
Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice.
    Neuroscience letters, 1997, Oct-03, Volume: 234, Issue:2-3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflamma

1997
Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine.
    Brain research, 1997, Sep-05, Volume: 767, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Estradio

1997
Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease.
    Brain research, 1997, Nov-28, Volume: 777, Issue:1-2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adenoviridae; Animals; Apomorphine; Behavior, Animal; Disease Models

1997
Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats.
    Progress in neuro-psychopharmacology & biological psychiatry, 1998, Volume: 22, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Depressive Disorder; Dopamine; Electric Stimulation; Electr

1998
In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
    Journal of neural transmission. Parkinson's disease and dementia section, 1995, Volume: 10, Issue:2-3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Homovanillic Acid; L

1995
Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats.
    European journal of pharmacology, 1998, Jul-17, Volume: 353, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Biotransformation; Corpus Striatum; D

1998
Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.
    Journal of neurochemistry, 1998, Volume: 71, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; 8,11,14-Eicosatrienoic Acid; Aged; Aged, 80 and over; Chromatography

1998
Enhancement of dopaminergic neurotoxicity by the mercapturate of dopamine: relevance to Parkinson's disease.
    Journal of neurochemistry, 2000, Volume: 74, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Apoptosis; Catechols; Dopamine; Neurotoxins

2000
Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures.
    Journal of neurochemistry, 2000, Volume: 74, Issue:4

    Topics: 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; 3,4-Dihydrox

2000
3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells.
    Brain research, 2000, Jun-23, Volume: 868, Issue:2

    Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Dopamine; Energy

2000
Manganese increases L-DOPA auto-oxidation in the striatum of the freely moving rat: potential implications to L-DOPA long-term therapy of Parkinson's disease.
    British journal of pharmacology, 2000, Volume: 130, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Animals; Ascorbic Acid; Chlorides; Chromatography, H

2000
Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum.
    Neurochemical research, 2000, Volume: 25, Issue:6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Bromocriptine; Corpus Striatum; Dopamine; Homovanillic Acid

2000
Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine.
    Neuroscience, 2000, Volume: 101, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cysteine; Dopamine; Down-Regulation; Extracellular Space; G

2000
The effect of GDNF on nigrostriatal dopaminergic function in response to a two-pulse K(+) stimulation.
    Experimental neurology, 2000, Volume: 166, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug

2000
The influence of pallidal deep brain stimulation on striatal dopaminergic metabolism in the rat.
    Neuroscience letters, 2000, Dec-22, Volume: 296, Issue:2-3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Denervation; Dopamine; Electric Stimulation Therapy; Globus

2000
Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.
    Free radical biology & medicine, 2001, Apr-15, Volume: 30, Issue:8

    Topics: 3,4-Dihydroxyphenylacetic Acid; 4-Aminobenzoic Acid; Aminobenzoates; Animals; Aristolochic Acids; Ce

2001
Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice.
    Journal of neurochemistry, 2001, Volume: 77, Issue:4

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino

2001
Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2001, Jun-15, Volume: 21, Issue:12

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Body Temperature; Casts, Sur

2001
Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
    Brain research, 2001, Jul-13, Volume: 907, Issue:1-2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dopamine; Dru

2001
Differentiation of human dopamine neurons from an embryonic carcinomal stem cell line.
    Brain research, 2001, Aug-31, Volume: 912, Issue:1

    Topics: 1-Methyl-3-isobutylxanthine; 3,4-Dihydroxyphenylacetic Acid; Cell Differentiation; Colforsin; Cultur

2001
3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis.
    Brain research. Molecular brain research, 2001, Sep-10, Volume: 93, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aldehydes; Brain; Catechols; Humans; Hydrogen Peroxide; Hydrox

2001
Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat.
    Redox report : communications in free radical research, 2001, Volume: 6, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal;

2001
COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2002, Volume: 109, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catech

2002
Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease.
    Brain research, 2002, Mar-15, Volume: 930, Issue:1-2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Dopam

2002
Oxidative metabolite of dopamine, 3,4-dihydroxyphenylacetaldehyde, induces dopamine release from PC12 cells by a Ca2+-independent mechanism.
    Brain research, 2002, Mar-22, Volume: 931, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Calcium; Calcium Channel Blockers; Dopamine; L-Lactate Dehy

2002
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2002, Apr-01, Volume: 22, Issue:7

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Behavior, Animal; Cell Count; Cell Death;

2002
The controlled conversion of human neural progenitor cells derived from foetal ventral mesencephalon into dopaminergic neurons in vitro.
    Brain research. Developmental brain research, 2002, May-30, Volume: 136, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Brain Tissue Transplantation; Brain-Derived Neurotrophic Factor; Cel

2002
Studies on urinary DOPAC in man by means of a sensitive automated procedure.
    Biochemical medicine, 1978, Volume: 19, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Addison Disease; Adrenal Gland Neoplasms; Adult; Aged; Autoanalysis;

1978
The simultaneous determination by selected ion monitoring of the levels of homovanillic, isohomovanillic, 3,4-dihydroxyphenylacetic and 3-methoxy-4-hydroxymandelic acids in single biological samples.
    Clinica chimica acta; international journal of clinical chemistry, 1975, Jul-23, Volume: 62, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Cats; Chromatography, Gas; Dihydroxyphenyl

1975
The Parkinsonian syndrome and its dopamine correlates.
    Advances in experimental medicine and biology, 1977, Volume: 90

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dopamine; Extrapyramidal Tracts; Female; Homovanillic A

1977
Dopamine correlates of neurological and psychological status in untreated Parkinsonism.
    Journal of neurology, neurosurgery, and psychiatry, 1976, Volume: 39, Issue:10

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Affect; Aged; Dopamine; Female; Homovanillic Acid; Humans; Le

1976
Effects of levodopa on the bladder outlet.
    The Journal of urology, 1975, Volume: 113, Issue:6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Dopamine; Female; Homovanillic Acid; Humans; Levodopa; Male; M

1975
Assessment of cerebrospinal fluid levels of dopamine metabolites by gas chromatography.
    Psychopharmacologia, 1975, Apr-30, Volume: 42, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Chromatography, Gas; Dopamine; Homovanillic Acid; Levodopa; Parkinso

1975
Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations.
    Clinical neurology and neurosurgery, 1975, Volume: 78, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Benserazide; Biogenic Amines; Dopamine; Female; Homovanillic Acid; H

1975
Therapy of Morbus Parkinson and radical-induced neurotoxicity in the rat--in vivo voltammetric studies.
    Journal of neural transmission. Supplementum, 1992, Volume: 38

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson

1992
Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material.
    Acta neuropathologica, 1992, Volume: 83, Issue:4

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Astrocytoma; Biopsy; Catecholamines; Caudate Nucleus; Child;

1992
Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
    Neuroscience letters, 1991, Feb-11, Volume: 123, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amin

1991
Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis.
    Journal of neural transmission. Parkinson's disease and dementia section, 1991, Volume: 3, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Autopsy; Bio

1991
Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat.
    Brain research bulletin, 1991, Volume: 26, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Aci

1991
Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice.
    Journal of neural transmission. Parkinson's disease and dementia section, 1991, Volume: 3, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aged; Animals; Cerebra

1991
Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis.
    Brain research, 1990, Jun-11, Volume: 519, Issue:1-2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Brain;

1990
Exogeneous expression of L-dopa and dopamine in various cell lines following transfer of rat and human tyrosine hydroxylase cDNA: grafting in an animal model of Parkinson's disease.
    Progress in brain research, 1990, Volume: 82

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; DNA; Dopamine; Enz

1990
Catechol metabolites in the cerebrospinal fluid as possible markers in the early diagnosis of Parkinson's disease.
    Neurology, 1991, Volume: 41, Issue:5 Suppl 2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catechols; Dopamine; Guinea Pigs; Humans; Oxidation-

1991
L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease.
    Clinical neuropharmacology, 1990, Volume: 13, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenethylami

1990
Decreased dopamine in the retinas of patients with Parkinson's disease.
    Investigative ophthalmology & visual science, 1990, Volume: 31, Issue:11

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Dopamine; Female; Homovanillic Acid; Humans

1990
GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice.
    Journal of the neurological sciences, 1990, Volume: 99, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani

1990
Corticoliberin, somatocrinin and amine contents in normal and parkinsonian human hypothalamus.
    Neuroscience letters, 1985, May-14, Volume: 56, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Biogenic Amines; Corticotropin-Releasing Hormone; Dopamine; Fe

1985
Manganese neurotoxicity: effects of L-DOPA and pargyline treatments.
    Brain research, 1986, Mar-05, Volume: 367, Issue:1-2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Drug Syn

1986
[Clinical significance of 3,4-dihydroxyphenyl acetic acid analysis in endocrine tests of the adrenal medulla and sympathetic nervous system].
    Nihon rinsho. Japanese journal of clinical medicine, 1989, Volume: 48 Suppl

    Topics: 3,4-Dihydroxyphenylacetic Acid; Addison Disease; Adrenal Gland Neoplasms; Adrenal Medulla; Adult; Ag

1989
CSF monamine metabolites in movement disorders and normal aging.
    Archives of neurology, 1985, Volume: 42, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dyskinesia, Drug-Induced; Dystonia; Female; Glycols; Ho

1985
Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism?
    Neuroscience letters, 1985, Apr-09, Volume: 55, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Aotus trivirg

1985
Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
    Biological psychiatry, 1986, Volume: 21, Issue:14

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholinesterase; Aged; Alzheimer Disease; Cerebrospinal Fluid P

1986
Bromocriptine holiday: effects on dopamine receptors and turning behavior in rats.
    Neurology, 1986, Volume: 36, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Binding Sites; Bromocriptine; Dopamine; D

1986
Biochemical aspects of Parkinson-dementia complex.
    European neurology, 1988, Volume: 28 Suppl 1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Dement

1988
Evaluation of the biological activity of several analogs of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Journal of neurochemistry, 1987, Volume: 48, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Corpus

1987
Behavioral and biochemical effects of nicotine in an MPTP-induced mouse model of Parkinson's disease.
    Pharmacology, biochemistry, and behavior, 1987, Volume: 28, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat

1987
[Psychiatric symptoms and plasma levodopa dynamics in Parkinson's disease].
    Rinsho shinkeigaku = Clinical neurology, 1987, Volume: 27, Issue:7

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Dopamine; Female; Hallucinations; Humans; L

1987
Biochemical effects of chronic L-dopa treatment in rats: implications for emergence of tolerance phenomena in patients with Parkinson's disease.
    Advances in neurology, 1987, Volume: 45

    Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Oral; Animals; Brain; Dopamine; Drug Administration

1987
Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues.
    Biochemical pharmacology, 1986, Mar-15, Volume: 35, Issue:6

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; Animals; Blood Platelets; Chromatography, High Pressure L

1986